Lott McGregor N, Schiffman Joyce C, Davis Janet L
Bascom Palmer Eye Institute, Miami, FL, USA.
Am J Ophthalmol. 2009 Nov;148(5):711-717.e2. doi: 10.1016/j.ajo.2009.06.010. Epub 2009 Aug 5.
To report the effect of intravitreal bevacizumab (Avastin; Genentech Inc, South San Francisco, California, USA) on visual acuity and macular thickness in patients with inflammatory choroidal neovascularization (CNV) or cystoid macular edema (CME).
Retrospective, noncomparative, interventional case series.
Each eye received 1.25 mg of intravitreal bevacizumab at baseline. Follow-up examinations were scheduled at 1- to 2-month intervals, with additional injections at the discretion of the physician. Comprehensive evaluations, including Snellen best-corrected visual acuity (BVCA) and optical coherence tomography measurements, were performed at each visit. Main outcome measures were BCVA and central subfield thickness (CST), as measured by optical coherence tomography.
Thirty-four eyes of 30 patients with inflammatory CNV (n = 21 eyes of 19 patients; 9 male, 10 female) or CME (n = 13 eyes of 11 patients; 4 male, 7 female) were identified. Median ages were 52 years (range, 7 to 83) and 67 years (range, 17 to 83) for the CNV and CME groups, respectively. The median length of follow-up for CNV eyes was 7 months (range, 1 to 28) while the median follow-up for CME eyes was 13 months (range, 1 to 20). Both groups received a median of two injections (range, 1 to 9 for CNV and 1 to 4 for CME). For eyes with CNV, BCVA improved significantly at follow-up month 1, but was not different from baseline thereafter; CST remained unchanged throughout follow-up. For eyes with CME, neither BCVA nor CST changed significantly over the course of follow-up.
Bevacizumab appears to stabilize BCVA and CST for eyes with inflammatory CNV or CME.
报告玻璃体内注射贝伐单抗（阿瓦斯汀；基因泰克公司，美国加利福尼亚州南旧金山）对炎症性脉络膜新生血管（CNV）或黄斑囊样水肿（CME）患者视力和黄斑厚度的影响。
回顾性、非对照、干预性病例系列研究。
每只眼在基线时接受1.25mg玻璃体内贝伐单抗注射。随访检查安排在1至2个月的间隔进行，根据医生的判断进行额外注射。每次就诊时进行全面评估，包括Snellen最佳矫正视力（BVCA）和光学相干断层扫描测量。主要观察指标为光学相干断层扫描测量的BCVA和中心子野厚度（CST）。
确定了30例炎症性CNV患者（19例患者的21只眼；9例男性，10例女性）或CME患者（11例患者的13只眼；4例男性，7例女性）的34只眼。CNV组和CME组的中位年龄分别为52岁（范围7至83岁）和67岁（范围17至83岁）。CNV眼的中位随访时间为7个月（范围1至28个月），而CME眼的中位随访时间为13个月（范围1至20个月）。两组均接受了中位两次注射（CNV组范围1至9次，CME组范围1至4次）。对于CNV眼，随访第1个月时BCVA显著改善，但此后与基线无差异；整个随访期间CST保持不变。对于CME眼，随访期间BCVA和CST均无显著变化。
贝伐单抗似乎能使炎症性CNV或CME眼的BCVA和CST稳定。
